TScan Therapeutics (TCRX)
(Real Time Quote from BATS)
$7.94 USD
-0.80 (-9.15%)
Updated May 29, 2024 02:54 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
TScan Therapeutics, Inc. [TCRX]
Reports for Purchase
Showing records 21 - 37 ( 37 total )
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UntitledTCR-T?s Continue Assault on Heme/Solid Tumors; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage at OUTPERFORM; Look No Further, TCRX Found Your Target
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Phase 1 Data of TSC-100 and TSC-101 Points Towards Future Positive Narrative
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TScan''s Pipeline Reports Progress On All Fronts (Liquid Solid Tumors); Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Newly Announced Amgen Partnership Highlights The Power of TargetScan
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Formidable TCR Platform Positioned for Future Growth; Reit. Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TScan Maps Out Solid Tumor Strategy at Investor Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Solid Tumor INDs on Horizon in 4Q22; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expanding TCR-T Programs On Track with Phase 1 Umbrella Data set for YE22; Reit. Buy and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TSC-200 Series Featured at KOL Event Underscore Tools to Unlock True Solid Tumor Prize
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data-Rich Year Ahead for TScan; Reit. Buy and Lowering Our PT to $15 From $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Growth Seen Across Pipeline; Reit. Buy and $21 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As CAR-T Programs Scream "Look at Me" During ASH, We Look to the Future Impact of TCR-Ts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TScan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Robust TCR Platform With a Clear Path Toward Liquid and Solid Tumors; Initiating With a Buy and $21 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A